表紙
市場調査レポート

癌治療の個別化医療における提携条件と契約

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 293210
出版日 ページ情報 英文 467 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
癌治療の個別化医療における提携条件と契約 Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016
出版日: 2016年09月01日 ページ情報: 英文 467 Pages
概要

当レポートでは、癌治療の個別化医療における提携契約について調査分析し、世界の主要な医療企業によって締結された各種契約の動向、主要取引、大規模取引について検証し、セグメント別の契約ディレクトリも含めて、概略以下の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 癌治療の個別化医療における契約の動向

  • イントロダクション
  • 長年にわたる癌治療の個別化医療における提携
  • 大手製薬会社の癌治療の個別化医療における契約活動
  • 最も活動的な癌治療の個別化医療
  • 癌治療の個別化医療における提携:取引タイプ別
  • 癌治療の個別化医療における提携:癌の種類別
  • 癌治療の個別化医療における提携:開発段階別
  • 癌治療の個別化医療における平均取引条件
  • 癌治療の個別化医療における提携の構造

第3章 癌治療の個別化医療における主要取引

  • イントロダクション
  • 癌治療の個別化医療における主要取引:金額別

第4章 大手製薬会社の癌治療の個別化医療における取引

  • イントロダクション
  • 大手製薬会社の提携取引の利用方法
  • 大手製薬会社の癌治療の個別化医療における提携企業プロファイル

第5章 癌治療の個別化医療における契約ディレクトリ

  • イントロダクション
  • 企業別
  • 開発段階別
  • 取引タイプ別
  • 癌の治療分野別

第6章 癌治療の個別化医療における契約ディレクトリ:固有の技術タイプ別

  • 個別化医療
  • 薬理ゲノミクス
  • バイオマーカー
  • コンパニオン診断

第7章 提携情報提供元

  • オンライン提携
  • 提携イベント
  • 契約に関する参考文献

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP22014

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading companies.

Comprehensive directory of personalized medicine in oncology deals since 2010

Personalized medicine in oncology contract documents

Personalized medicine in oncology agreement terms

Personalized medicine in oncology agreement structure

Top personalized medicine in oncology deals by value

Most active personalized medicine in oncology dealmakers

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2010. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2010. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report scope

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 includes:

  • Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2010
  • Analysis of personalized medicine in oncology deal structure
  • Case studies of real-life personalized medicine in oncology deals
  • Access to over 700 personalized medicine in oncology deals
  • The leading personalized medicine in oncology deals by value since 2010
  • Most active personalized medicine in oncology dealmakers since 2010
  • The leading personalized medicine in oncology partnering resources

In Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Specific technology target
  • Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Benefits

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of personalized medicine in oncology deal trends since 2010
  • Analysis of the structure of personalized medicine in oncology agreements with numerous real life case studies
  • Comprehensive access to over 700 personalized medicine in oncology deals entered into by the world's biopharma companies
  • Detailed access to actual personalized medicine in oncology contracts entered into by leading biopharma companies
  • Insight into the terms included in a personalized medicine in oncology agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Personalized Medicine in Oncology dealmaking

  • 2.1. Introduction
  • 2.2. Personalized Medicine in Oncology partnering over the years
  • 2.3. Most active Personalized Medicine in Oncology dealmakers
  • 2.4. Personalized Medicine in Oncology partnering by deal type
  • 2.5. Personalized Medicine in Oncology partnering by therapy area
  • 2.6. Deal terms for Personalized Medicine in Oncology partnering
    • 2.6.1 Personalized Medicine in Oncology partnering headline values
    • 2.6.2 Personalized Medicine in Oncology deal upfront payments
    • 2.6.3 Personalized Medicine in Oncology deal milestone payments
    • 2.6.4 Personalized Medicine in Oncology royalty rates

Chapter 3 - Leading Personalized Medicine in Oncology deals

  • 3.1. Introduction
  • 3.2. Top Personalized Medicine in Oncology deals by value

Chapter 4 - Most active Personalized Medicine in Oncology dealmakers

  • 4.1. Introduction
  • 4.2. Most active Personalized Medicine in Oncology dealmakers
  • 4.3. Most active Personalized Medicine in Oncology partnering company profiles

Chapter 5 - Personalized Medicine in Oncology contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Personalized Medicine in Oncology contracts dealmaking directory

Chapter 6 - Personalized Medicine in Oncology dealmaking by technology type

  • Biomarkers
  • Companion diagnostics
  • Personalised medicine
  • Pharmacogenomics

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Personalized Medicine in Oncology deals by company A-Z
  • Appendix 2 - Personalized Medicine in Oncology deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Appendix 3 - Personalized Medicine in Oncology deals by deal type
  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Appendix 4 - Personalized Medicine in Oncology deals by therapy area
  • Bladder cancer
  • Bone cancer
  • Brain cancer
  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Endometrial
  • Esophageal cancer
  • Gastric cancer
  • Head and neck cancer
  • Kidney cancer
  • Leukemia
  • Acute lymphoblastic leukemia
  • Acute myelogenous leukemia
  • Chronic lymphocytic leukemia
  • Chronic myelogenous leukemia
  • Liver cancer
  • Lung cancer
  • Non small cell lung cancer
  • Lymphoma
  • Non Hodgkin's lymphoma
  • Melanoma
  • Mesothelioma
  • Metastases
  • Multiple myeloma
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Renal cell carcinoma
  • Sarcoma
  • Solid tumors
  • Symptoms
  • Oral mucositis
  • Testicular cancer
  • Thyroid cancer
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Personalized Medicine in Oncology partnering since 2010
  • Figure 2: Active Personalized Medicine in Oncology dealmaking activity- 2010 to 2016
  • Figure 3: Personalized Medicine in Oncology partnering by deal type since 2010
  • Figure 4: Personalized Medicine in Oncology partnering by disease type since 2010
  • Figure 5: Personalized Medicine in Oncology deals with a headline value
  • Figure 6: Personalized Medicine in Oncology deals with an upfront value
  • Figure 7: Personalized Medicine in Oncology deals with a milestone value
  • Figure 8: Personalized Medicine in Oncology deals with a royalty rate value
  • Figure 9: Top Personalized Medicine in Oncology deals by value since 2010
  • Figure 10: Most active Personalized Medicine in Oncology dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top